Reboldi Lab
@reboldilab.bsky.social
Reposted by Reboldi Lab
Excited to be part of this Women in STEM Viepoint 🌟 Huge thanks to @jem.org for the invite - what an inspiring lineup!
In this Viewpoint, we hear from a cross section of women, across multiple research fields, discussing their science and the process of setting up a lab as an independent researcher. rupress.org/jem/article/...
@quinascience.bsky.social @aweinstock.bsky.social @osterhoutlab.bsky.social
#WomeninSTEM
@quinascience.bsky.social @aweinstock.bsky.social @osterhoutlab.bsky.social
#WomeninSTEM
September 18, 2025 at 4:28 PM
Excited to be part of this Women in STEM Viepoint 🌟 Huge thanks to @jem.org for the invite - what an inspiring lineup!
Reposted by Reboldi Lab
Why does selection feel so weak relative to mutation in affinity maturation? A new blog post giving three perspectives, including our new transformer-based model of natural selection on antibodies: matsen.group/general/202...
The term 'affinity maturation' understates the influence of somatic hypermutation
Three recent papers quantify how nucleotide-level mutation processes drive antibody evolution.
matsen.group
August 19, 2025 at 5:17 PM
Why does selection feel so weak relative to mutation in affinity maturation? A new blog post giving three perspectives, including our new transformer-based model of natural selection on antibodies: matsen.group/general/202...
Reposted by Reboldi Lab
Dr. Andrea Reboldi from UMass Chan Medical School 🇺🇸 will be presenting his work on "Metabolic regulation of intestinal humoral response". Check his recent study on how receptor signaling controls gut humoral response:
pubmed.ncbi.nlm.nih.gov/37714151/
@reboldilab.bsky.social
#EMBOBarrierTissues
pubmed.ncbi.nlm.nih.gov/37714151/
@reboldilab.bsky.social
#EMBOBarrierTissues
May 29, 2025 at 8:35 AM
Dr. Andrea Reboldi from UMass Chan Medical School 🇺🇸 will be presenting his work on "Metabolic regulation of intestinal humoral response". Check his recent study on how receptor signaling controls gut humoral response:
pubmed.ncbi.nlm.nih.gov/37714151/
@reboldilab.bsky.social
#EMBOBarrierTissues
pubmed.ncbi.nlm.nih.gov/37714151/
@reboldilab.bsky.social
#EMBOBarrierTissues
Reposted by Reboldi Lab
🚨🦠🔬 Last month to register to the EMBO workshop on Adaptive Immunity in Barrier Tissues.
📍 Where: Basel, Switzerland
📅 When: 26th–29th August 2025
📝 Registration deadline: 30th May 2025
Childcare support & travel grants from @embo.org and @efis-immunology.bsky.social
#EMBOBarrierTissues
📍 Where: Basel, Switzerland
📅 When: 26th–29th August 2025
📝 Registration deadline: 30th May 2025
Childcare support & travel grants from @embo.org and @efis-immunology.bsky.social
#EMBOBarrierTissues
Adaptive immunity in barrier tissues
Immune responses lie at the heart of almost every aspect of human health, including host responses to infection, autoimmunity, cancer, metabolism and aging. While adaptive immune responses by B and T…
meetings.embo.org
April 30, 2025 at 3:04 PM
🚨🦠🔬 Last month to register to the EMBO workshop on Adaptive Immunity in Barrier Tissues.
📍 Where: Basel, Switzerland
📅 When: 26th–29th August 2025
📝 Registration deadline: 30th May 2025
Childcare support & travel grants from @embo.org and @efis-immunology.bsky.social
#EMBOBarrierTissues
📍 Where: Basel, Switzerland
📅 When: 26th–29th August 2025
📝 Registration deadline: 30th May 2025
Childcare support & travel grants from @embo.org and @efis-immunology.bsky.social
#EMBOBarrierTissues
Reposted by Reboldi Lab
Kellog, @reboldilab.bsky.social, Vanni et al. reveal that #microbiome-driven tuft cells’ hyperplasia in the colon helps defend against Clostridioides difficile infection. https://buff.ly/3CRIPNy
📘 In Host–Microbe Interactions 2025 👉 https://buff.ly/40XMv8r
📘 In Host–Microbe Interactions 2025 👉 https://buff.ly/40XMv8r
February 19, 2025 at 8:16 PM
Kellog, @reboldilab.bsky.social, Vanni et al. reveal that #microbiome-driven tuft cells’ hyperplasia in the colon helps defend against Clostridioides difficile infection. https://buff.ly/3CRIPNy
📘 In Host–Microbe Interactions 2025 👉 https://buff.ly/40XMv8r
📘 In Host–Microbe Interactions 2025 👉 https://buff.ly/40XMv8r
Reposted by Reboldi Lab
Follow our new podcast for more Mucosal Immunology - #MucosalMondays, coming to you the last Monday of every month.
It's Coming! The Mucosal Immunology Podcast to launch on MONDAY! 🌟
Explore groundbreaking insights and inspiring stories in the world of mucosal immunology - brought to you by SMI and @mucosalimmunol.bsky.social.
#MucosalImmunology #SciencePodcast #ImmunologyResearch #PodcastLaunch
Explore groundbreaking insights and inspiring stories in the world of mucosal immunology - brought to you by SMI and @mucosalimmunol.bsky.social.
#MucosalImmunology #SciencePodcast #ImmunologyResearch #PodcastLaunch
January 27, 2025 at 10:42 PM
Follow our new podcast for more Mucosal Immunology - #MucosalMondays, coming to you the last Monday of every month.
Reposted by Reboldi Lab
Registration is live!! May 30th deadline for #EMBOTissueImmunity in Basel🇨🇭 (home to Eurocup 2025, Eurovision 2025, Art Basel, world renowned architecture and muuuuuch more!) Be our guest for groundbreaking #immunology discussion, swimming & fun along the Rhine.
meetings.embo.org/event/25-bar...
meetings.embo.org/event/25-bar...
December 19, 2024 at 1:59 PM
Registration is live!! May 30th deadline for #EMBOTissueImmunity in Basel🇨🇭 (home to Eurocup 2025, Eurovision 2025, Art Basel, world renowned architecture and muuuuuch more!) Be our guest for groundbreaking #immunology discussion, swimming & fun along the Rhine.
meetings.embo.org/event/25-bar...
meetings.embo.org/event/25-bar...
Reposted by Reboldi Lab
Toronto-based ImmVue Therapeutics Inc. has licensed cancer-fighting technology from UMass Chan Medical School: direc.to/m4zC
This partnership was facilitated by BRIDGE Innovation and Business Development at UMass Chan.
This partnership was facilitated by BRIDGE Innovation and Business Development at UMass Chan.
UMass Chan licenses potential small molecule immunotherapeutic for cancer treatment to ImmVue Therapeutics Inc.
Toronto-based ImmVue Therapeutics Inc. has exclusively licensed allosteric small molecule compounds identified in the laboratory of Joonsoo Kang.
direc.to
December 12, 2024 at 1:57 PM
Toronto-based ImmVue Therapeutics Inc. has licensed cancer-fighting technology from UMass Chan Medical School: direc.to/m4zC
This partnership was facilitated by BRIDGE Innovation and Business Development at UMass Chan.
This partnership was facilitated by BRIDGE Innovation and Business Development at UMass Chan.
Reposted by Reboldi Lab
Speaker line up for #EMBOTissueImmunity to take place in Basel 🇨🇭 26-29 August 2025. Come join @maurogaya.bsky.social and I for some fantastic #immunology along the Rhine! Please share this invitation - we hope you will join us. Registrations will be open soon.
December 10, 2024 at 12:57 PM
Speaker line up for #EMBOTissueImmunity to take place in Basel 🇨🇭 26-29 August 2025. Come join @maurogaya.bsky.social and I for some fantastic #immunology along the Rhine! Please share this invitation - we hope you will join us. Registrations will be open soon.
Reposted by Reboldi Lab
Microbiome-derived succinate-driven tuft cell hyperplasia in the colon helps defend against Clostridioides difficile infection, providing a pathway through which host/microbe interactions protect against pathogens
doi.org/10.1084/jem....
@reboldilab.bsky.social
@jexpmed.bsky.social
doi.org/10.1084/jem....
@reboldilab.bsky.social
@jexpmed.bsky.social
Succinate-producing microbiota drives tuft cell hyperplasia to protect against Clostridioides difficile
The microbial metabolite succinate promotes tuft cell hyperplasia, which enhances the gut’s ability to protect against intestinal infections. This study re
doi.org
November 26, 2024 at 8:17 PM
Microbiome-derived succinate-driven tuft cell hyperplasia in the colon helps defend against Clostridioides difficile infection, providing a pathway through which host/microbe interactions protect against pathogens
doi.org/10.1084/jem....
@reboldilab.bsky.social
@jexpmed.bsky.social
doi.org/10.1084/jem....
@reboldilab.bsky.social
@jexpmed.bsky.social